Please login to the form below
Kisplyx
This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.
NICE gives green light to Ipsen's Cabometyx
Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
Latest news
-
Eisai wins EU licence for kidney cancer drug Kisplyx
Under brand name Lenvima, Kisplyx was granted US marketing authorisation in May this year, the drug having received breakthrough and priority review status by the FDA. ... Analysts are now suggesting that with Kisplyx's approval in two key markets, plus
-
HIV prevention pill heads July CHMP recommendations
Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's Cabometyx (cabozantinib) and Eisai's Kisplyx (lenvatinib
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
-
Senior Copywriter
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer opens AI-enabled drug discovery center in UK
- Spotlight interview: 15 minutes on PR in pharma
- Changing healthcare, one film at a time
- Faisal Ahmed joins healthcare comms agency Sudler London
- Red Consultancy appoints MD in its health division
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Wilmington Healthcare appoints new consultants
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
Quick links
Infographics
